Illumina, Inc. (ETR:ILU)
80.53
-0.49 (-0.60%)
Jun 27, 2025, 5:35 PM CET
Illumina Revenue
Illumina had revenue of $1.04B USD in the quarter ending March 30, 2025, a decrease of -3.25%. This brings the company's revenue in the last twelve months to $4.34B, down -3.47% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.34B
Revenue Growth
-3.47%
P/S Ratio
3.10
Revenue / Employee
$480.29K
Employees
9,030
Market Cap
12.40B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Illumina News
- 3 days ago - Dr. Lal PathLabs boots genomics capabilities with Illumina’s NovaSeq™ X Series - Business Upturn
- 4 days ago - SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push - Benzinga
- 5 days ago - Standard BioTools jumps on sale of SomaLogic to Illumina - Seeking Alpha
- 5 days ago - Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy - PRNewsWire
- 9 days ago - Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling - Business Wire
- 17 days ago - lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - PRNewsWire
- 4 weeks ago - Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PRNewsWire
- 4 weeks ago - Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha